slide1 n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
Lancet 373:1765-72, 2009 PowerPoint Presentation
Download Presentation
Lancet 373:1765-72, 2009

Loading in 2 Seconds...

  share
play fullscreen
1 / 15
sakura

Lancet 373:1765-72, 2009 - PowerPoint PPT Presentation

165 Views
Download Presentation
Lancet 373:1765-72, 2009
An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Lancet 373:1765-72, 2009

  2. Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose-lowering versus Standard Treatment Kay et al, Lancet 373:1765-72, 2009

  3. Study Design of Clinical Trials to Compare Intensive glucose-lowering versus Standard Treatment Kay et al, Lancet 373:1765-72, 2009

  4. Event Rates of Cardiovascular Outcomes of Intensive-Lowering versus Standard Treatments Kay et al, Lancet 373:1765-72, 2009

  5. Probability of events of non-fatal myocardial infarction with intensive glucose-lowering vs. standard treatment Ray et al, Lancet 2009; 373: 1765–72

  6. Probability of events of coronary heart disease with intensive glucose-lowering vs. standard treatment

  7. Probability of events of stroke with intensive glucose-lowering versus standard treatment Ray et al, Lancet 2009; 373: 1765–72

  8. Probability of events of all-cause mortality with intensive glucose-lowering versus standard treatment Ray et al, Lancet 2009; 373: 1765–72

  9. Annals Internal Medicine 2009; 151: 394-403

  10. Pooled relative risk and risk differences (per 1000 patients over 5 years of treatment) estimates of nonfatal MI, fatal MI, nonfatal stroke, fatal stroke, and PAD UKPDS 34 UKPDS 34 ACCORD ADVANCE VADT Kelly et al, Ann Inter Med 2009; 151: 394-403

  11. Pooled relative risk and risk differences (per 1000 patients over 5 years of treatment) estimates of nonfatal MI, fatal MI, nonfatal stroke, fatal stroke, and PAD Kelly et al, Ann Inter Med 2009; 151: 394-403

  12. Pooled relative risk and risk differences (per 1000 patients over 5 years of treatment) estimates of severe hypoglycemia Kelly et al, Ann Inter Med 2009; 151: 394-403

  13. Summary of Meta-Analysis • These 2 meta-analysis found that, compared with conventional control, intensive glucose control reduce the risk for cardiovascular disease (mostly nonfatal myocardial infarction) but not for cardiovascular death or all-cause mortality, and increased risk for severe hypoglycemia. • Early trials suggested possible decreased risk for death with intensive control, whereas some more recent trials suggested possible increased risk for death with more stringent control.